Fibrosis in Renal Allografts
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00493194|
Recruitment Status : Unknown
Verified October 2005 by University Hospital, Antwerp.
Recruitment status was: Recruiting
First Posted : June 28, 2007
Last Update Posted : November 26, 2008
This prospective, randomized study, comparing sirolimus to cyclosporine in renal transplant recipients, has two major objectives:
-To determine the incidence and the degree of interstitialfibrosis and arteriosclerosis, as wel as the glomerular volume in protocol biopsies at 6 months in sirolimus-and in cyclosporine-treated renal allograft recipients, by means of quantitative computerized image analysis.
- To determine the prognostic implication of these morphologic changes.
- To study the expression of genes, involved in inflammation and fibrosis, in protocol biopsies at 6 months in sirolimus-and cyclosporine-treated renal allograft recipients.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Failure, Chronic Transplantation Immunosuppression Interstitial Fibrosis||Drug: sirolimus Drug: cyclosporine Drug: daclizumab||Phase 4|
Calcineurin inhibitors have significantly improved the one-year graft survival of renal allografts. However, chronic nephrotoxicity caused by calcineurin inhibitors contributes to the long-term decline in renal function in kidney transplant recipients. Approximately ninety percent of the protocol biopsies of renal allografts, performed at 18 months post transplantation, show histological lesions of chronic calcineurin nephrotoxicity . In recent years, two new non-nephrotoxic immunosuppressive drugs, i.e. mycophenolate mofetil and sirolimus, have become available for the prophylaxis of graft rejection in renal transplantation.
Three randomized clinical trials, comparing cyclosporine with sirolimus in combination with mycophenolate mofetil, reported a superior graft function at one year in sirolimus treated renal allograft recipients. However, data on long-term graft survival and histological lesions of protocol biopsies in sirolimus-treated renal transplant recipients, are currently lacking.
In analogy with previous observations in native kidney disease, Grimm et al. recently reported that interstitial fibrosis in protocol biopsies of renal allografts, at 6 months post transplantation, significantly inversely correlates with the subsequent graft survival One hundred recipients of a first renal allograft will be randomized to an immunosuppressive protocol based on cyclosporine (50 patients) or sirolimus (50 patients). Concommittant immunosuppression will be similar in both groups, and consists of Daclizumab as induction treatment (five iv gifts every two weeks), and mycophenolate mophetil and steroids as maintenance immunosuppression.
Randomization will be performed by centre to avoid centre-related bias. All patients will complete a follow-up of 12 months. Two core biopsies of the graft will be obtained in each recipient, at implantation and at 6 months. Serum creatinine and the estimated creatinine clearance (by the Nankivell and the Jellife method) will be monthly recorded.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic)|
|Study Start Date :||May 2005|
|Estimated Study Completion Date :||July 2007|
- The primary end-point of this study will be the cortical fractional interstitial fibrosis volume (V IntFib) in protocol biopsies at 6 months. The V IntFib will be determined on Sirius red stained slides by means of a computerized image analysis program,
- Secundary end-points:
- -Patient and graft-survival at one year.
- -The serum creatinine and the estimated creatinine
- clearance at 6 and 12 months.
- -The 24 hour proteinuria at 6 and 12 months.
- -The intimal area and arterial wall thickness in protocol
- biopsies at 6 months.
- -The glomerular volume in protocol biopsies at 6 months.
- -The incidence of acute rejection episodes during the
- first year.
- -The severity of acute rejection episodes according to
- the Banffâ 97 classification.
- -The incidence of infectious complications.
- -The incidence of hematological adverse effects.
- -The number of antihypertensive and lipid-lowering drugs
- at 6 and 12 months.
- -The incidence of treatment failure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00493194
|Contact: Jean-Louis Bosmans, MD Ph.D||..32/3/821 37 92||JeanLouis.Bosmans@ua.ac.be|
|Contact: Angelika Jurgens, Coordinator||..32/3/821.34.68||Angelika.Jurgens@uza.be|
|University Hospital Antwerp||Recruiting|
|Edegem, Antwerp, Belgium, 9260|
|Contact: Jean-Louis Bosmans, M.D. Ph.D. ..32/3/821 37 92 JeanLouis.Bosmans@ua.ac.be|
|Contact: Angelika Jurgens, Coordinator ..32/3/821.34.68 Angelika.Jurgens@uza.be|
|Principal Investigator: Jean-Louis Bosmans, MD. Ph.D.|
|University Hospital Brussels||Recruiting|
|Brussels (Jette), Brabant, Belgium, 1090|
|Contact: Jacques Sennesael, M.D. ..32/2/477.60.55 email@example.com|
|Contact: Katrien Van Bever, Study-nurse ..32/2/477.60.55 Katrien.VanBever@az.vub.ac.be|
|Principal Investigator: Jacques Sennesael, M.D.|
|University Hospital Gent||Recruiting|
|Gent, Oost-Vlaanderen, Belgium, 9000|
|Contact: Patrick Peeters, M.D. ..32/9/240.45.13 firstname.lastname@example.org|
|Contact: Cathy Vandermeulen, Study-Nurse ..32/9/240.61.68 Cathy.Vandermeulen@uzgent.be|
|Principal Investigator: Patrick Peeters, M.D.|
|Principal Investigator:||Jean-Louis Bosmans, M.D. Ph.D.||University Hospital, Antwerp|